Author

K. J. Johnson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Pharmacology & Toxicology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 4 Organism:human· 4 Assay:proteomics· 3 Research Focus:differential expression· 2 Organism:mouse· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

A. M. Kurimchak· 2 shared C. D. Pernici· 2 shared C. S. Metcalf· 2 shared E. J. Dahle· 2 shared J. Duncan· 2 shared K. S. Wilcox· 2 shared P. J. West· 2 shared A. M. Jermakowicz· 1 shared

Activity by Year

2020-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. M. Kurimchak

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Resistance to Naive and Formative Pluripotency Conversion in RSeT Human Embryonic Stem Cells

K. G. Chen, K. J. Johnson, K. Park, D. Maric, F. Yang, W. F. Liu, Y. C. Fann, B. S. Mallon, P. G. Robey

This study characterizes a new pluripotent state in RSeT hESCs, showing resistance to naive and formative conversion and distinct transcriptomic and signaling features.

bioRxiv · Feb 16, 2024 · PreprintCell Biology

RAPID RESISTANCE TO BET INHIBITORS IS MEDIATED BY FGFR1 IN GLIOBLASTOMA

A. M. Jermakowicz, A. M. Kurimchak, K. J. Johnson, F. Bourgain-Guglielmetti, S. Kaeppeli, M. Affer, H. Pradhyumnan, R. Suter, W. Walters, M. Cepero, J. Duncan, N. G. Ayad

This study identifies rapid resistance to BET inhibitors in glioblastoma mediated by FGFR1 and shows that co-targeting BET and FGFR1 synergizes to reduce tumor growth.

bioRxiv · Dec 19, 2023Cancer Biology

Evaluation of spontaneous seizure activity, sex-dependent differences, behavioral comorbidities, and alterations in CA1 neuron firing properties in a mouse model of Dravet Syndrome

C. D. Pernici, A. Spink, E. J. Dahle, K. J. Johnson, C. S. Metcalf, P. J. West, K. S. Wilcox

bioRxiv · Jun 16, 2021 · PreprintPharmacology & Toxicology

Development of an Antiseizure Drug Screening Platform for Dravet Syndrome at the NINDS contract site for the Epilepsy Therapy Screening Program

C. D. Pernici, J. A. Mensah, E. J. Dahle, K. J. Johnson, L. J. Handy, L. L. Buxton, M. D. Smith, P. J. West, C. S. Metcalf, K. S. Wilcox

This paper evaluates a mouse model of Dravet syndrome for antiseizure drug screening, finding that it is highly refractory to common ASDs but responsive to specific treatments like clobazam and valproic acid.

bioRxiv · Dec 1, 2020Pharmacology & Toxicology

Identification of Wee1 as Target in Combination with Avapritinib for the Treatment of Gastrointestinal Stromal Tumors

S. Ye, D. Sharipova, M. Kozinova, L. Klug, J. D'Souza, M. G. Belinsky, K. J. Johnson, M. B. Einarson, K. Devarajan, Y. Zhou, S. Litwin, M. C. Heinrich, R. DeMatteo, M. von Mehren, J. Duncan, L. Rink

This study identifies Wee1 as a therapeutic target in combination with avapritinib for treating gastrointestinal stromal tumors (GIST) by analyzing kinome profiles and conducting functional assays.

bioRxiv · Jun 7, 2020Cancer Biology

Kinome Profiling of Primary Endometrial Tumors Using Multiplexed Inhibitor Beads and Mass Spectrometry Identifies SRPK1 As Candidate Therapeutic Target

K. J. Johnson, V. Kumar, A. M. Kurimchak, N. Srivastava, S. Peri, K. Q. Cai, G. M. Mantia-Smaldone, J. S. Duncan

The paper develops a SILAC-based MIB-MS workflow to profile the kinome in endometrial tumors, identifying SRPK1 as a potential therapeutic target.

bioRxiv · Mar 3, 2020Cancer Biology